Pyxis Oncology shares surge 10.36% intraday as H.C. Wainwright maintains Buy rating with $5.00 price target.

Pyxis Oncology surged 10.36% intraday after H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating with a $5.00 price target. The move follows the firm’s reaffirmation of confidence in Pyxis’s clinical data, signaling optimism about its therapeutic pipeline and potential market performance. The analyst’s positive outlook aligns with the stock’s upward trajectory, reflecting renewed investor interest in the biopharmaceutical company’s development progress.